NCT07042113 - A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Atopic Dermatitis

Interventions

DRUG

new formulations of 611

Subjects will receive new formulations of 611 300mg once subcutaneous injection on D1

DRUG

existing formulations of 611

Subjects will receive existing formulations of 611 300mg once subcutaneous injection on D1

Trial Locations (2)

The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou

Shanghai General Hospital, Shanghai

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY